Risk of toxic epidermal necrolysis and Stevens-Johnson syndrome associated with benzodiazepines: a population-based cohort study
- 426 Downloads
We aim to estimate the incidence of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) among tetrazepam users and compare it with benzodiazepine users in a Spanish primary care database (BIFAP). The incidence in the general population (GenPop) and among phenytoin new users (as a positive control) was also estimated.
We identified a cohort of GenPop free of SJS/TEN (N = 3,155,364). Cohort entry was the date after 1 year of register with the physician during 2001–2011. No age restrictions were applied. Patients were followed from entry up to the first of the following: a record of SJS/TEN (potential cases), death, end of information, or December 2011. History of potential cases were manually reviewed blinded to exposure and considered “probable” when diagnosed in referral reports. Three cohorts of patients newly prescribed with benzodiazepines (N = 531,813), tetrazepam (N = 343,568), or phenytoin (N = 4993) were extracted from the GenPop cohort. Incidence rate (cases per million person-years (py)) for the GenPop and cumulative incidence (per million new users) during the first 9 weeks after each drug prescription were computed.
In the GenPop, 48 probable cases (38 SJS and 10 TEN) were identified (3.21/million py; 3.37 in men and 2.94 in women). In the benzodiazepines cohort, 2 probable TEN cases was identified (3.76/mill.). In the tetrazepam cohort, 1 probable SJS/TEN case was identified (2.91/mill.). In the phenytoin cohort, 4 probable cases (2 SJS and 2 TEN) were identified (801.12/mill.).
The incidence of SJS/TEN in tetrazepam users was very rare and similar to benzodiazepines users. The incidence in the GenPop and among users of phenytoin agreed with the literature.
KeywordsStevens-Johnson syndrome Toxic epidermal necrolysis Tetrazepam Benzodiazepines Phenytoin Incidence Cohort study
The authors would like to acknowledge the excellent collaboration of general practitioners and pediatricians taking part in BIFAP.
FdA collaboration was supported by a research grant from the Instituto de Salud Carlos III—Ministerio de Ciencia e Innovación (Grant No. PI12/02267).
Conflict of interest
The authors declare that they have no conflict of interest. The views expressed here do not necessarily represent the views of the co-authors’ respective companies or organizations.
- 3.Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F et al (1995) Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333(24):1600–1607. doi: 10.1056/nejm199512143332404 CrossRefPubMedGoogle Scholar
- 4.Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS (2005) Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol : Off Publ Am Coll Allergy Asthma Immunol 94(4):419–436. doi: 10.1016/s1081-1206(10)61112-x, quiz 436–418, 456CrossRefGoogle Scholar
- 5.Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A (2008) Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR study. J Invest Dermatol 128(1):35–44. doi: 10.1038/sj.jid.5701033 CrossRefPubMedGoogle Scholar
- 7.Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau JC (2002) Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 138(8):1019–1024CrossRefPubMedGoogle Scholar
- 9.Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, Walker AM (1990) The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 126(1):43–47CrossRefPubMedGoogle Scholar
- 13.Rzany B, Mockenhaupt M, Baur S, Schröder W, Stocker U, Mueller J, Holländer N, Bruppacher R, Schöpf E (1996) Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): structure and results of a population-based registry. J Clin Epidemiol 49(7):769–773CrossRefPubMedGoogle Scholar
- 14.Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M (2008) Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol 58(1):33–40. doi: 10.1016/j.jaad.2007.08.039 CrossRefPubMedGoogle Scholar
- 16.Tetrazepam containing medicines suspended across the EU (2014) European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Tetrazepam_containing_medicinal_products/human_referral_prac_000015.jsp&mid=WC0b01ac05805c516f. Accessed 4 July 2014
- 18.BIFAP Base de Datos para la Investigación Farmacoepidemiológica en Atención Primaria. http://bifap.aemps.es/. Accessed 05 March 2015
- 19.Lamberts H, Wood M (1987) ICPC. International classification of primary care. Oxford University Press, OxfordGoogle Scholar
- 20.Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, Haustein UF, Vieluf D, Roujeau JC, Le Louet H (2010) ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case–control analysis. Clin Pharmacol Ther 88(1):60–68. doi: 10.1038/clpt.2009.252 CrossRefPubMedGoogle Scholar
- 21.Moore N, Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jove J, Pariente A, Blin P, Benichou J, Begaud B (2013) Choice of the denominator in case population studies: event rates for registration for liver transplantation after exposure to NSAIDs in the SALT study in France. Pharmacoepidemiol Drug Saf 22(2):160–167. doi: 10.1002/pds.3371 CrossRefPubMedGoogle Scholar
- 22.Greenland S, Rothman KJ (2008) Introduction to stratified data. In: Rothman KJ, Greenland S, Lash TL (eds) Modern epidemiology, 3rd edn. Philadelphia, PA: Lippincott, Williams & Wilkins.Google Scholar
- 25.Pellkofer M, Paulig M (1989) Comparative double-blind study of the effectiveness and tolerance of baclofen, tetrazepam and tizanidine in spastic movement disorders of the lower extremities. Med Klin (Munich, Germany : 1983) 84(1):5–8Google Scholar
- 26.Enquete officielle sur les effects indesirables du tetrazepam (2012) Commission Nationale de Pharmacovigilance. Agence nationale de sécurité du médicament et des produits de santé. http://ansm.sante.fr/var/ansm_site/storage/original/application/c9e15dee904acc094f9b909eea1634a2.pdf. Accessed 14 July 2014
- 28.Tetrazepam adverse events and side effects reported to the FDA (AERS). DrugCite. Food and Drug Administration. http://www.drugcite.com/?q=tetrazepam. Accessed 15 July 2014
- 30.Sanchez I, Garcia-Abujeta JL, Fernandez L, Rodriguez F, Quinones D, Duque S, Lopez R, Jerez J (1998) Stevens-Johnson syndrome from tetrazepam. Allergol Immunopathol 26(2):55–57Google Scholar
- 40.Huerta C, Abbing-Karahagopian V, Requena G, Oliva B, Alvarez Y, Gardarsdottir H (2013) Prevalence of use of benzodiazepines and related drugs in seven European databases: a cross-national descriptive study from the PROTECT-EU project. Pharmacoepidemiol Drug Saf 22(1):1–512. doi: 10.1002/pds.3512 CrossRefGoogle Scholar
- 41.The RegiSCAR Project. (2014) RegiSCAR. http://www.regiscar.org/. Accessed 3 October 2014
- 43.PIELenRed (2014) Consorcio PIELenRed. http://pielenred.hol.es/PIELenRed/tag/pielenred/. Accessed 8 October 2014